Systematic review of 7 trials (6 meta-analysed, 472 men) with oligometastatic prostate cancer: metastasis-directed therapy plus standard care improved progression-free survival vs standard care (HR 0.44); overall survival benefit was not significant (HR 0.63, p=0.051).
Meta-analysisn = 472
Tang et al. Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration